Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

hAd5 ACE2 decoy - ImmunityBio

Drug Profile

hAd5 ACE2 decoy - ImmunityBio

Alternative Names: ACE2 Decoy COVID-19 Therapeutic - ImmunityBio; ACE2 Triple Decoy - ImmunityBio; ACE2(N27Y/H34A/H374N)-IgG1FC fusion protein decoy; ACE2(T27Y/H34A/H374N)-IgG1FC Triple Decoy; SARS-CoV-2 Neutralising ACE2 Decoy - ImmunityBio

Latest Information Update: 21 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunityBio
  • Class COVID-19 vaccines; Protein vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 11 Mar 2021 ImmunityBio plans a clinical trial for COVID-2019 infections
  • 09 Mar 2021 Early research in COVID-2019 infections in USA (unspecified route)
  • 09 Mar 2021 Immunogenicity data from preclinical studies for COVID-2019 infections released by ImmunityBio
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top